The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair ...
Cerevance will now speak with the FDA about next steps for solengrapas in Parkinson’s disease. Credit: PeopleImages / Shutterstock.com. Boston-based biotech Cerevance’s first-in-class Parkinson’s ...
Migraine involves recurrent attacks of moderate to severe head pain, frequently accompanied by sensitivity to light and sound. Credit: Tunatura/Shutterstock.com. Merz Therapeutics has concluded ...
Vanda has put the late-stage programme for VQW-765 in SAD on ice at it assesses the full dataset. Credit: omahgrafisgk / Shutterstock.com. Vanda Pharmaceuticals has hit pause on a late-stage programme ...
Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small ...
The trial randomised 274 participants to subcutaneous Taltz or the combination, alongside counselling on diet and physical activity. Credit: Pixel-Shot/Shutterstock.com. Eli Lilly and Company has ...
The trial intends to use the clinical findings to guide the future development of PLT012 across liver disease. Credit: Shidlovski/Shutterstock.com. Pilatus Biosciences has dosed the first patient in ...
A major focus of R&D in the Alzheimer’s disease therapeutic space is preventing the accumulation of amyloid beta.
BMS announced data from two pivotal trials, with both showing success. Credit: PixelBiss / Shutterstock.com Bristol Myers Squibb (BMS) has seen success in two pivotal trials, one in idiopathic ...
Obuprazine functions as a dopamine D2/D3 receptor partial agonist, a 5-HT1A receptor partial agonist, and a 5-HT2A receptor antagonist. Credit: Antonio Marca/Shutterstock.com. Tortugas Neuroscience ...
Efzimfotase alfa offered numerical, but not statistically significant improvements in patient six-minute walk test values in the HICKORY trial in hypophosphatasia. Credit: Lemberg Vector studio / ...
Mirum plans to file a sNDA for Livmarli in the first half 0f 2027. Credit: Vectomart / Shutterstock.com. Mirum Pharmaceuticals’ marketed therapy, Livmarli (maralixibat), could be poised for a label ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results